Filter by
Interviewing at Formation BioFebruary 16, 2024

Navigating the Formation Values Interview

The Formation Values Interview (FVI) is a distinctive component of the hiring process at Formation Bio, focused on evaluating candidates' alignment with our core values.

Read More
Introducing Formation Bio featured image

As we advance on our journey toward building the pharma company of the future, TrialSpark is now officially Formation Bio.

Read More
Working at Formation BioSeptember 1, 2023

Pay Transparency at Formation Bio

We disclose salary ranges for all open roles at Formation Bio. Learn more about our compensation philosophy.

Read More
Mission and Purpose at Formation Bio featured image

There are several thousand known human diseases, yet we only have FDA-approved treatments for about 500 of them. Patients are desperately waiting for more. We are building the pharma company of the future designed to bring new treatments to patients faster than ever before.

Read More

Select News Highlights

Partnership with major pharmaceutical company

Formation Bio (formerly known as TrialSpark) announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies.

Licensing of potential osteoarthritis treatment

Formation Bio (formerly known as TrialSpark) licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio.

Licensing of multiple immunodermatology assets

Formation Bio (formerly known as TrialSpark) announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio.

Pipeline growth at Formation Bio

After years of running trials for other drugmakers, Formation Bio (formerly known as TrialSpark) is building its own pipeline.

For media inquiries, get in touch with our press team.

© Formation Bio 2024
Site Credit